drugset / Trial / NCT03664960
An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 2, open-label, extension study to assess the safety and tolerability of AK002, given monthly for up to 26 doses.
Timeline
- Start
- 2018-11-14
- Primary completion
- 2021-11-02
- Completion
- 2021-11-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | lirentelimab | Monoclonal antibody | 3 mg/kg | — |